Malarone

Proguanil hydrochloride and atovaquone, the active ingredients in Malarone, form an antimalarial (antiprotozoal) combination presented as a tablet for oral administration. The product is indicated for the prevention of malaria and for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum in both adults and children traveling to endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple markets globally.

Malarone is used in the antimalarial therapeutic class to prevent and treat malaria caused by Plasmodium species.

Prevention of malaria: provides chemoprophylaxis for travelers to endemic regions. Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: clears infection in patients. Post‑exposure prophylaxis: used after a potential mosquito bite when travel to an endemic area has occurred.

Malarone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset or queasiness. - Headache: transient headache. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: signs of liver injury including jaundice or elevated liver enzymes. - Hemolytic anemia: especially in patients with G6PD deficiency (rare).

Before prescribing Malarone, clinicians should consider several precautionary measures to ensure safe use.

Assess renal function: dose adjustment may be required in severe renal impairment. Evaluate hepatic status: use with caution in patients with liver disease. Pregnancy safety: category B; discuss risks and benefits with pregnant women. Breastfeeding: weigh potential infant exposure against maternal benefit. Concomitant medications: review for interactions that may affect drug levels. Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Malarone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Rifampicin: induces metabolism and reduces atovaquone levels, compromising efficacy. - Antiretroviral protease inhibitors (e.g., ritonavir): increase atovaquone concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Digoxin: atovaquone can increase serum digoxin; check levels. - Cimetidine: may raise proguanil concentrations; observe for side effects.